Galectin Therapeutics Inc. (GALT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.01, Bloomberg Earnings reports. During the same period in the prior year, the business posted ($0.20) earnings per share.
Galectin Therapeutics (NASDAQ:GALT) opened at 1.72 on Monday. Galectin Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.68. The company has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.21. The firm’s market capitalization is $59.63 million.
A hedge fund recently raised its stake in Galectin Therapeutics stock. Northern Trust Corp raised its stake in Galectin Therapeutics Inc. (NASDAQ:GALT) by 4.4% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,097 shares of the company’s stock after buying an additional 3,176 shares during the period. Northern Trust Corp owned 0.22% of Galectin Therapeutics worth $185,000 as of its most recent SEC filing. 11.00% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/14/galectin-therapeutics-inc-galt-releases-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.
Several research firms have recently issued reports on GALT. ValuEngine lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $2.25.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.